(Q39163549)

9 September 2017

title

Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. (English)

1 reference

9 September 2017

main subject

phase I clinical trial

0 references

author

Allan Saul

2

1 reference

9 September 2017

Lawrence GW

1

1 reference

9 September 2017

Giddy AJ

3

1 reference

9 September 2017

Kemp R

4

1 reference

9 September 2017

Pye D

5

1 reference

9 September 2017

language of work or name

English

0 references

publication date

1 February 1997

1 reference

9 September 2017

1 reference

9 September 2017

volume

15

1 reference

9 September 2017

issue

2

1 reference

9 September 2017

page(s)

176-178

1 reference

Adjuvants--a balance between toxicity and adjuvanticity

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900150-8

7 January 2021

Use of novel adjuvants and delivery systems to improve the humoral and cellular immune response to malaria vaccine candidate antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900150-8

7 January 2021

Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900150-8

7 January 2021

Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720).

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2896%2900150-8

7 January 2021

10.1016/S0264-410X(96)00150-8

Identifiers

DOI

1 reference

9 September 2017

1 reference